

1 **The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-**
2 **aminoquinoline antimalarial therapies: a pooled analysis of individual participant data.**

3 Leen N Vanheer, MD^{1*}, Jordache Ramjith, PhD^{2*}, Almahamoudou Mahamar, PhD^{3*}, Merel
4 J Smit, MD², Kjerstin Lanke², Michelle E Roh, PhD⁴, Koualy Sanogo, MD³, Youssouf Sinaba,
5 MD³, Sidi M. Niamebele, PharmD³, Makonon Diallo, MD³, Seydina O Maguiraga, MD³,
6 Sekouba Keita, MS³, Siaka Samake, PharmD³, Ahamadou Youssouf PharmD³, Halimatou
7 Diawara, MD³, Sekou F. Traore, PhD³, Roly Gosling, MD^{5,6}, Joelle M Brown, PhD⁶, Chris
8 Drakeley, PhD¹, Alassane Dicko, MD^{3†}, Will Stone, PhD^{1†}, Teun Bousema, PhD^{2†}

9
10 ¹Department of Infection Biology, London School of Hygiene & Tropical Medicine, London,
11 UK, WC1E7HT

12 ²Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud
13 University Medical Center, Nijmegen, the Netherlands

14 ³Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and
15 Dentistry, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali

16 ⁴Institute for Global Health Sciences, University of California, San Francisco, CA, USA.

17 ⁵Department of Disease Control, London School of Hygiene and Tropical Medicine, London
18 UK.

19 ⁶Department of Epidemiology and Biostatistics, University of California, San Francisco, CA,
20 USA.

21

22 * Joint first authors, contributed equally

23 [†]NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Joint first authors, contributed equally

24 Corresponding author: Teun Bousema: teun.bousema@radboudumc.nl

25

26 **Abbreviations**

27 ACT, artemisinin-based combination therapy; AL, Artemether-lumefantrine; AL-AQ;
28 Artemether-lumefantrine-amodiaquine; AQ, Amodiaquine; AS-AQ, Artesunate-
29 Amodiaquine; DHA-PPQ, Dihydroartemisinin-Piperaquine; G6PD; glucose-6-phosphate
30 dehydrogenase; PY-AS, Pyronaridine-Artesunate; PQ, Primaquine; SLD, Single low-dose;
31 RT-qPCR, reverse-transcriptase quantitative PCR; SP-AQ, Sulfadoxine-pyrimethamine plus
32 Amodiaquine; TACT, Triple artemisinin-based combination therapy; TQ, Tafenoquine; WHO,
33 World Health Organisation.

34 ABSTRACT

35 **Background:** Interrupting human-to-mosquito transmission is important for malaria
36 elimination strategies as it can reduce infection burden in communities and slow the spread of
37 drug resistance. Antimalarial medications differ in their efficacy in clearing the transmission
38 stages of *Plasmodium falciparum* (gametocytes) and in preventing mosquito infection. Here
39 we present a combined analysis of six trials conducted at the same study site with highly
40 consistent methodologies that allows for a direct comparison of the gametocytocidal and
41 transmission-blocking activities of fifteen different antimalarial regimens or dosing schedules.

42 **Methods and findings:** Between January 2013 and January 2023, six clinical trials with
43 transmission endpoints were conducted at the Clinical Research Centre of the Malaria Research
44 and Training Centre of the University of Bamako in Mali. These trials tested Artemisinin-
45 Combination Therapies (ACTs), non-ACT regimens and combinations with 8-
46 aminoquinolines. Participants were males and non-pregnant females, between 5-50 years of
47 age, who presented with *P. falciparum* mono-infection and gametocyte carriage by
48 microscopy. Blood samples were taken before and after treatment for thick film microscopy,
49 infectivity assessments by mosquito feeding assays and molecular quantification of
50 gametocytes. Mixed-effects generalized linear models were fit with individual-specific random
51 effects and fixed effects for time points, treatment groups and their interaction. Models
52 quantified changes in mosquito infection rates and gametocyte densities within treatment arms
53 over time and between treatments. In a pooled analysis of 422 participants, we observed
54 substantial differences between ACTs in gametocytocidal and transmission-blocking activities,
55 with artemether-lumefantrine (AL) being significantly more potent at reducing mosquito
56 infection rates within 48 hours than dihydroartemisinin-piperaquine (DHA-PPQ), artesunate-
57 amodiaquine (AS-AQ) and pyronaridine-artesunate (PY-AS) ($p < 0.0001$). The addition of
58 single low dose primaquine (SLD PQ) accelerated gametocyte clearance and led to a

59 significantly greater reduction in mosquito infection rate within 48-hours of treatment for each
60 ACT, while an SLD of the 8-aminoquinoline tafenoquine (TQ) showed a delayed but effective
61 response compared to SLD primaquine. Finally, our findings confirmed considerably higher
62 post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ)
63 compared to most ACTs, with a significantly lower relative reduction in mosquito infection
64 rate at day 7 compared to DHA-PPQ, AS-AQ, and AL ($p < 0.0001$). Therefore, adding an SLD
65 PQ to SP-AQ may be beneficial to block malaria transmission in community treatment
66 campaigns.

67 **Conclusions:** We found marked differences among ACTs and single low-dose 8-
68 aminoquinoline drugs in their ability and speed to block transmission. The findings from this
69 analysis can support treatment policy decisions for malaria elimination and be integrated into
70 mathematical models to improve the accuracy of predictions regarding community
71 transmission and the spread of drug resistance under varying treatment guidelines.

72 INTRODUCTION

73 The primary aim in the therapeutic management of malaria is the clearance of pathogenic
74 asexual blood-stage parasites, using antimalarials with schizonticidal properties. Artemisinin-
75 based combination therapies (ACTs) are the first-line treatment for uncomplicated *Plasmodium*
76 *falciparum* malaria across the world and are highly potent against asexual parasites, capable of
77 reducing the circulating asexual parasite biomass ~10,000 fold per 48 hour cycle (1).
78 Gametocytes are distinct parasite stages that are not associated with symptoms but are the only
79 parasite life stage that can be transmitted to and establish infection in mosquitoes. In *P.*
80 *falciparum*, gametocytes develop during five developmental stages over a prolonged 10–12-
81 day maturation period. Importantly, *P. falciparum* gametocytes have markedly different
82 sensitivity profiles to antimalarial drugs than asexual parasites. Assessing and comparing the
83 gametocytocidal and transmission-blocking properties of different antimalarial regimens is
84 important for informing treatment guidelines that aim to contribute to transmission reduction.

85 Artemisinins are active against developing gametocytes but less so against the mature forms
86 (2). Although gametocyte density generally decreases more after treatment with ACTs
87 compared to non-ACTs (3), there is considerable variation in gametocyte-clearing potential
88 between ACTs (4). For example, current artemisinin partner drugs such as piperazine,
89 lumefantrine and amodiaquine have limited activity against *P. falciparum* gametocytes at
90 clinically relevant concentrations (2,5–7). *In vitro* data for the partner drug pyronaridine are
91 contradictory; one study found a strong effect against mature gametocytes (8), whereas others
92 only observed activity against mature gametocytes at concentrations above the therapeutic
93 threshold (2,6,9). Furthermore, a disconnect exists between the detection of gametocytes and
94 infectivity to mosquitoes; on the one hand, gametocytes can be infectious at sub-microscopic
95 densities (10), whereas on the other, antimalarials can have a parasite-inhibiting effect, active

96 after ingestion by mosquitoes (2,11) or sterilise gametocytes so that these are detectable but
97 not transmissible (12). Gametocyte quantification is therefore an imperfect measure of post-
98 treatment transmission potential, and mosquito feeding assays are considered more informative
99 (13).

100 With the threat of artemisinin partial resistance in sub-Saharan Africa (14), various strategies
101 have been proposed to counter the spread of resistant parasites. One of the most promising
102 approaches, according to modelling simulations, is the use of Triple Artemisinin-based
103 Combination Therapies (TACT), that combine existing ACTs with a second partner drug. This
104 approach may offer protection against partner drug resistance and maintain high treatment
105 efficacy in areas where resistance against artemisinins and one of the partner drugs is present
106 (15). Other suggested strategies include multiple first-line ACT therapies or cycling between
107 different ACTs (16,17). An alternative or complementary strategy is to supplement treatment
108 with gametocytocidal compounds. Primaquine (PQ) and its long-lasting analogue tafenoquine
109 (TQ) are 8-aminoquinolines that can clear *P. vivax* liver stages (18) and have *P. falciparum*
110 gametocytocidal activity. The WHO recommends supplementing first-line ACTs with a single
111 low-dose (0.25mg/kg) PQ (SLD PQ) in low transmission areas (19), and the WHO malaria
112 policy and advisory group has now suggested expanding this recommendation to other regions
113 (20). TQ holds the promise of long-lasting transmission blocking activity and recently a single-
114 low dose of TQ (SLD TQ) in combination with ACTs and non-ACT treatments was found to
115 effectively block transmission within 7 days at a dose of 1.66 mg/kg (21,22). To date, no trials
116 directly comparing SLD TQ to SLD PQ have been conducted, largely due to the impracticality
117 of trials involving mosquito feeding assays.

118 In order to make informed decisions regarding optimal antimalarial regimens, it is necessary
119 to understand and compare the transmission-blocking abilities of different ACTs and TACTs.

120 We conducted a pooled analysis of individual-level data from six clinical trials to compare the
121 transmission-blocking effects of 15 different antimalarials and combinations. All six trials
122 measured mosquito transmission endpoints, used sensitive gametocyte quantification, and were
123 conducted using the same mosquito feeding protocols and assays in Ouélessébougou, Mali,
124 between 2013 and 2023 (21–26). Results from this analysis can be used in mathematical models
125 to more accurately predict community transmission and the spread of drug resistance under
126 different treatment guidelines, and will inform malaria control programmes.

127 **METHODS**

128 **Study design and participants**

129 Between January 2013 and January 2023, six clinical trials (21–26) (Table 1) (appendix 2)
130 involving a total of 521 participants were performed at the Clinical Research Centre of the
131 Malaria Research and Training Centre (MRTC) of the University of Bamako (Bamako, Mali).
132 Study participants were recruited in the commune of Ouélessébougou, which includes the
133 central town of Ouélessébougou and 44 surrounding villages, with an estimated 50,000
134 inhabitants and located approximately 80 km south of Bamako, the capital of Mali. Malaria
135 transmission in this region is hyperendemic and highly seasonal with incidence peaking during
136 and following the rainy season from July to November. In all six trials, participants were males
137 and non-pregnant females, between 5-50 years of age, with a body weight less than 80 kg, who
138 presented with *P. falciparum* mono-infection and at least 1 (study acronyms PQ03, NECTAR
139 1-4) or 2 (study PQ01) gametocytes per 500 white blood cells (WBC) detected by blood smear.
140 This minimum gametocyte density corresponds to an approximate minimum of 16-32
141 gametocytes per μL of blood when assuming 8000 WBC per μL . Participants in all studies,
142 except for the 2013-2014 PQ01 study, were exclusively asymptomatic, and four studies (study
143 acronyms PQ01, PQ03, NECTAR2, NECTAR3) required participants to have normal glucose-
144 6-phosphate dehydrogenase (G6PD) production, as determined by OSMMR-D-D calorimetric
145 test (R&D Diagnostics, Aghia Paraskevi, Greece; studies PQ01, NECTAR2 and NECTAR3),
146 CareStart G6PD rapid diagnostic test (Access Bio, Somerset, NJ,USA; study PQ03) and/or
147 STANDARD G6PD quantitative enzyme activity test (SD Biosensor, Suwon, South Korea;
148 studies NECTAR2 and NECTAR3; table 1, appendix 2). Other study-specific inclusion criteria
149 are presented in appendix 2.

150 Ethical approvals for the individual studies were obtained from the Ethics Committee of the
151 Faculty of Medicine, Pharmacy, and Dentistry of the University of Science, Techniques, and
152 Technologies of Bamako (Bamako, Mali). In addition, the studies were approved by the
153 Committee on Human Research at the University of California (San Francisco, CA, USA),
154 and/or the Research Ethics Committee of the London School of Hygiene and Tropical Medicine
155 (London, UK).

156 **Procedures**

157 Of the antimalarial treatments evaluated in the included studies, the following were included
158 in this analysis: i) Dihydroartemisinin-piperaquine (DHA-PPQ; Eurartesim; Sigma Tau,
159 Gaithersburg, MD, USA); ii) Pyronaridine-artesunate (PY-AS; Pyramax; Shin Poong
160 Pharmaceutical, Seoul, South Korea); iii) Artemether-lumefantrine (AL; Coartem; Novartis,
161 Basel, Switzerland or Guilin Pharmaceutical, Shanghai, China); iv) Artesunate-amodiaquine
162 (AS-AQ; Guilin Pharmaceutical, Shanghai, China); v) Sulfadoxine-pyrimethamine plus
163 amodiaquine (SP-AQ; Guilin Pharmaceutical, Shanghai, China); vi) Any of the ACTs listed
164 above plus a single low-dose of primaquine (ACT-PQ; 0.25 or 0.5 mg/kg; Sanofi, Laval, QC,
165 Canada or ACE Pharmaceuticals, Zeewolde, the Netherlands); vii) Non-ACT (SP-AQ) plus a
166 single low-dose of primaquine (Non-ACT-PQ; Sanofi, Laval, QC, Canada); viii) ACT (DHA-
167 PPQ) plus a single low dose of tafenoquine (ACT-TQ; 0.83 or 1.66 mg/kg; 60° Pharmaceuticals
168 Ltd, USA) (Table 1). Antimalarial treatments were administered as per manufacturer's
169 instructions (supplementary Information 1 for dosing tables and supplementary Table 1 for
170 manufacturers, appendix 1, pp 3-6) under direct supervision. ACT treatments and sulfadoxine-
171 pyrimethamine plus amodiaquine were administered over 3 days (days 0, 1, and 2). Primaquine
172 and tafenoquine were administered as a single dose immediately after the first dose of ACT. In
173 the NECTAR1 study, participants were treated with a full course of DHA-PPQ at day 21 of

174 follow-up, to prevent re-infection. For the current analysis, we did not consider study arms
175 within the included studies that are currently not considered as treatment regimens, such as
176 arms with PQ doses below 0.25 mg/kg (n=33 participants) and with TQ doses below 0.83
177 mg/kg (n=20). Likewise, treatment arms involving methylene blue (n=20) or the combination
178 of SP-AQ with an SLD TQ (n=20) were not considered in the analysis.

179 In all studies, blood samples were taken before treatment and on days 2 and 7 following
180 treatment for thick film microscopy, infectivity assessments and molecular analysis of
181 gametocyte density, as outlined in Figure 1 and described in detail in appendix 2.

182 For infectivity assessments in all studies, 75-90 insectary-reared *Anopheles gambiae* females
183 were allowed to feed for 15–20 min on venous blood samples collected in Lithium Heparin
184 tubes and offered in a water-jacketed membrane feeder system, as previously described (27).
185 Fully fed mosquitoes were kept in a temperature and humidity-controlled insectary until day 7
186 post-feeding, and then dissected in 1% mercurochrome to detect and quantify *P. falciparum*
187 oocysts. Giemsa-stained blood slides were double read by expert research microscopists with
188 asexual stages counted against 200 white blood cells and gametocytes counted against 500
189 white blood cells. For molecular gametocyte quantification in all studies, venous or finger-
190 prick blood collected in EDTA tubes was aliquoted into L6 buffer (Severn Biotech,
191 Kidderminster, UK) or RNA protect cell reagent (Qiagen, Hilden, Germany) and stored at
192 $\leq -70^{\circ}\text{C}$ until total nucleic acid extraction using a MagNAPure LC automated extractor (Total
193 Nucleic Acid Isolation Kit High Performance; Roche Applied Science, Indianapolis, IN, USA).
194 Male and female gametocytes were quantified in a multiplex reverse-transcriptase quantitative
195 PCR (RT-qPCR) assay targeting Pfs25 or CCP4 transcripts for female gametocytes and
196 PfMGET for male gametocyte quantification, as specified in appendix 2. Molecular
197 gametocyte quantification was repeated for the PQ03 study, after the original density estimates

198 of this study (but not of other studies) showed marked disagreement with their respective
199 microscopy density measurements (supplementary figure 1, appendix 1, p 7). Samples were
200 classified as negative for a specific gametocyte sex if the RT-qPCR quantified gametocyte
201 density was less than 0.01 gametocytes per μL (equivalent to one gametocyte per 100 μL of
202 the blood sample).

203 **Statistical analysis**

204 Asexual parasite and microscopy gametocyte density distributions at baseline were presented
205 per study by violin plots. Six individuals from the PQ01 study that lacked baseline infectivity
206 measures or microscopy gametocyte densities were excluded from analysis. The association
207 between gametocyte density (gametocytes / μL) on a log₁₀ scale and the proportion of infected
208 mosquitoes was determined by a mixed-effects logistic regression with a random effect for
209 study. The association between (log₁₀) gametocyte density estimates by microscopy and
210 molecular methods was determined by a linear model with an interaction by study.

211 To quantify reductions in key output parameters (gametocyte prevalence and densities, the
212 proportion of infected mosquitos, mean oocyst density) within treatments over time (days 2, 7
213 and 14) and between treatments at each time point, mixed-effects generalized linear models
214 were fit with individual-specific random effects and fixed effects for time points, treatment
215 groups and their interaction. A Poisson family with log-link was used for gametocyte
216 prevalence (since a binomial family with log-link failed to converge), a Gamma family with
217 log-link was used for gametocyte densities assessed by microscopy and RT-qPCR, a binomial
218 family with log-link was used for proportion of infected mosquitos, while a negative binomial
219 family with log-link was used for oocyst density.

220 The models were of the form:

$$221 \quad y_i = \exp \left(\beta_0 + \sum_{k=1}^8 \beta_{1k} \times arm_{ik} + \sum_{j=0}^3 \beta_{2j} \times t_{ij} + \sum_{k=1}^8 \sum_{j=0}^3 \beta_{3kj} \times arm_{ik} \times t_{ij} + Z_i \right),$$

222 where the study arms were DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ
223 and ACT-TQ, and the time points were t_0 =day 0, t_1 =day 2, t_2 =day 7 and t_3 =day 14, the β 's
224 are the regression parameters to be estimated, Z_i are the individual specific random effects, and
225 y_i is one of the outcomes of interest: gametocyte prevalence or densities, the proportion of
226 infected mosquitos, oocyst density. The beta (β) coefficients estimated from the model were
227 used to calculate the relative reductions at each time point for each treatment arm.

228 Kaplan-Meier survival curves were generated with the *survfit* function from the R-based
229 *survival* package to display the cumulative probability of remaining uncleared of gametocytes
230 detected by microscopy, gametocytes detected by RT-qPCR and any infectivity to mosquitoes.
231 The Cox proportional hazards model was used to estimate hazard ratios and to draw
232 comparisons between treatment arms for each of the clearance events. Statistical analyses and
233 visualisations were conducted in R (version 4.3.2).

234 The original studies were registered with ClinicalTrials.gov (NCT01743820, NCT02831023,
235 NCT04049916, NCT04609098, NCT05081089 and NCT05550909).

236

237 RESULTS

238 A total of 422 study participants (42-100 participants per study) and 15 different treatment
239 regimens or dosing schedules were evaluated across the six included trials (20-79 participants
240 per regimen/dosing schedule, Table 1, Appendix 2). Parasite density was broadly similar
241 between studies that recruited asymptomatic parasite carriers (2016-2022) but higher in the
242 PQ01 study conducted in 2013-2014 where clinical malaria patients were eligible (Figure 2A).
243 Although participants were recruited based on microscopically detected gametocyte carriage,
244 at the time of enrolment (up to 24 hours after the initial screening), microscopy gametocyte
245 prevalence was 99.5% (420/422) with a median gametocyte density of 55 (IQR 32-112)
246 gametocytes/ μ L among gametocyte carriers (Figure 2B). Gametocyte density by microscopy
247 was highly skewed with a range of 15.5-2720 gametocytes/ μ L (supplementary table 2,
248 appendix 1, p 8). Prior to treatment, 68.8% (290/422) of individuals were infectious to
249 mosquitoes (Figure 2C). The proportion of mosquitoes each participant infected at this time
250 point ranged from 0.75% to 94.3% and was positively associated with microscopically
251 determined gametocyte density (Figure 2D). In the four studies where oocyst numbers were
252 recorded (NECTAR studies 1-4), the proportion of mosquitoes infected was strongly positively
253 associated with mosquito infection burden (oocyst density) (supplementary figure 2, appendix
254 1, p 9).

255 Acknowledging that densities below the microscopic threshold for detection (16 gametocytes/
256 μ L) can result in mosquito infections, gametocyte density was also quantified by molecular
257 methods. For all studies, gametocyte prevalence by molecular methods was 100% at enrolment
258 and there was a strong positive association between gametocyte density by microscopy and by
259 molecular methods (Figure 3A). At enrolment, two study participants were positive for

260 gametocytes by molecular methods but not by microscopy; both became gametocyte positive
261 by microscopy one day after baseline.

262 Following treatment, gametocyte prevalence and densities declined in all treatment groups. The
263 extent and speed at which this occurred depended strongly on the treatment provided (Figure
264 3B-D, supplementary figure 3, appendix 1, p 10). Two days after treatment, relative reductions
265 compared to baseline in microscopically detected gametocyte prevalence were non-significant
266 in all arms. However, at seven days after treatment initiation, this reduction was statistically
267 significant in the AL group (51.12%, 95% CI 3.85% -75.15%, $p=0.0381$), but not after the
268 other schizonticidal regimens without addition of a gametocytocide ($p=0.2258$, $p=0.3892$,
269 $p=0.5731$ and $p=0.7997$ after DHA-PPQ, SP-AQ, PY-AS and AS-AQ treatment, respectively).
270 The reduction in gametocyte prevalence was more rapid for treatment groups that included a
271 single low-dose gametocytocide, with reductions of 68.31% (95% CI 10.02% -88.84%,
272 $p=0.0309$) in the non-ACT-PQ group, 90.52% (95% CI 78.52% -95.81%, $p<0.0001$) in the
273 ACT-PQ group and 61.53% (95% CI 16.07% -82.37%, $p=0.0164$) in the ACT-TQ group, at
274 day 7 compared to baseline. Relative reductions in gametocyte prevalence assessed by
275 microscopy and molecular methods at days 2, 7 and 14 post-treatment are presented in Figure
276 3B and supplementary tables 3-8 (appendix 1, pp 11-16). We combined different ACTs with
277 PQ for this analysis; the findings per study arm are given in supplementary figure 4 (appendix
278 1, p17).

279 Reductions in gametocyte prevalence were predictably slower than reductions in gametocyte
280 densities, which showed significant relative reductions at day 2 compared to baseline by both
281 microscopy and molecular measures in the AL ($p=0.0116$ and $p<0.0001$, respectively) and
282 ACT-PQ ($p=0.0003$ and $p<0.0001$, respectively) groups (Figure 3 C-D, supplementary tables
283 9-14, supplementary figure 5, appendix 1, pp 18-24). Reductions in PCR-determined

284 gametocyte density on day 2 after initiation of treatment were more pronounced for AL
285 compared to DHA-PPQ ($p=0.0036$), SP-AQ ($p=0.0308$), PY-AS ($p=0.0302$) (supplementary
286 table 12, appendix 1, p 21) with similar patterns at day 7 and 14 (supplementary tables 13 and
287 14, appendix 1, p 22-23). AS-AQ also resulted in a smaller reduction in gametocyte density
288 compared to AL, which was not significant on day 2 ($p=0.1085$) but became significant at later
289 timepoints ($p=0.0617$ and $p=0.0013$ at days 7 and 14). ACT-PQ resulted in the fastest
290 reductions in molecular gametocyte density and this reduction was significantly larger than the
291 best performing ACT, AL, on days 7 and 14 ($p<0.0001$; supplementary tables 13 and 14,
292 appendix 1, pp 22-23). Non-ACT-PQ and ACT-TQ regimens showed reductions of nearly 30%
293 in gametocyte density by PCR on day 2, which was significantly less than in the ACT-PQ
294 group ($p=0.0400$ and $p=0.0043$, respectively). Across all post-treatment timepoints, the
295 proportion of gametocyte infections that were submicroscopic was 28.63% (777/2714).

296 A valuable feature of the studies included was the availability of mosquito infection data before
297 and after initiation of treatment. In all groups, 58.3% to 95% of participants infected
298 mosquitoes before treatment (supplementary table 2, appendix 1, p 8), with 99.7% (289/290)
299 of infectious individuals having gametocytes detected by microscopy at this timepoint.
300 Following treatment, as gametocyte densities declined, the contribution of submicroscopic
301 infections to transmission increased (Figure 4A). At day 2, 8.33% (12/144) of all infectious
302 individuals had submicroscopic gametocyte infections. At days 7 and 14, these percentages
303 were 6.59% (6/91) and 3.70% (1/27), respectively. The experiments in which mosquitoes
304 became infected after feeding on samples with submicroscopic gametocyte densities typically
305 resulted in low proportions of infected mosquitoes.

306 Transmission blocking effects per treatment group were quantified as averages of individual
307 level effects; that is, within-person reductions in the proportion of mosquitoes infected at post-

308 treatment timepoints compared to baseline (Figure 4B, supplementary figures 6 and 7,
309 appendix 1, pp 28-29). All treatment groups showed a statistically significant relative reduction
310 in mosquito infection rates by day 14 (Figure 4B, supplementary tables 15-17, appendix 1, pp
311 25-27). At earlier time-points, we observed a modest but statistically significant reduction in
312 mosquito infection prevalence on day 2 for DHA-PPQ (20.35%, 95% CI 12.70-27.33,
313 $p < 0.0001$) and for non-ACT-PQ (83.26%, 95% CI 78.11-87.21, $p < 0.0001$) whilst $>90\%$
314 transmission reduction was observed for AL and for ACTs with SLD PQ. For AS-AQ and ACT
315 with SLD TQ, a statistically significant reduction in mosquito infection rates was only observed
316 at day 7, while for SP-AQ and PY-AS, this was only observed by day 14. For these treatment
317 groups, relative differences in infection rates at day 2 ranged from reductions of 2.17% in the
318 SP-AQ arm (95% CI -12.80% -15.14%) to increases in infectivity in the AS-AQ arm
319 ('reduction' of -17.32%, 95% CI -42.92-3.69); neither of these findings were statistically
320 significant. Taken together, AL performed significantly better at reducing mosquito infection
321 rate within 48 hours of treatment, compared to the other ACT regimens DHA-PPQ, PY-AS
322 and AS-AQ at day 2 ($p < 0.0001$ compared to AL) (Figure 5A). The differences in reductions in
323 infectivity became overall smaller at day 7 after treatment (Figure 5B), however, SP-AQ and
324 PY-AS still only showed a $<10\%$ reduction, while the reduction in mosquito infection was
325 increased in the DHA-PPQ and AS-AQ groups to 41.51% (95% CI 34.98% - 47.37%) and
326 55.32% (95% CI 39.21% - 67.16%), respectively

327 Over all treatment groups, 27 individuals became infectious to mosquitoes after treatment while
328 initially not infecting mosquitoes; 13.92% (11/79) of participants in DHA-PPQ groups, 12.5%
329 (5/40) in SP-AQ groups, 16% (4/25) in the PY-AS group, 10% (2/20) in the AS-AQ group,
330 1.67% (1/60) in AL groups, 0.72% (1/138) in the ACT plus primaquine groups and 7.5% (3/40)
331 in ACT plus tafenoquine groups. The probability of infecting at least one mosquito was reduced
332 predictably slower than the mosquito infection rate, with only the groups with PQ reaching

333 >90% reduction in this probability at day 2, followed by AL that achieved >80% reduction at
334 day 7 and ACT-TQ that achieved this at day 14 (supplementary Figure 8, supplementary Tables
335 18-20, appendix 1 pp 30-33). Relative reductions in oocyst density in dissected mosquitoes
336 preceded the reduction in mosquito infection rates in certain treatment groups, such as DHA-
337 PPQ, SP-AQ, PY-AS and AS-AQ, where a larger reduction in oocyst density was found prior
338 to observing the same level of reduction in mosquito infection rate (supplementary Figure 9,
339 supplementary tables 21-23, appendix 1 pp 34-37).

340 The clearance of infectivity (i.e. no longer infecting any mosquitoes) preceded the clearance of
341 gametocytes assessed by both microscopy and RT-qPCR (Figure 6). The treatment groups with
342 SLD PQ exhibited the fastest infectivity clearance, followed by those treated with AL (hazard
343 ratios 0.62 ($p < 0.0001$) and 0.66 ($p = 0.0006$) compared to non-ACT-PQ and ACT-PQ,
344 respectively). Infectivity was annulled by day 7 in the AL, ACT-PQ and non-ACT-PQ groups,
345 and by day 14 in the ACT-TQ group, while this effect was slower in the SP-AQ (day 28), DHA-
346 PPQ (day 35) and PY-AS (day 35) groups. Not all infectivity was cleared by the end of follow
347 up (day 28) in the AS-AQ group (4.55 % of individuals still infectious, 95% CI 0.67-30.85).
348 Hazard ratios and between-arm comparisons for the clearance of infectivity, adjusted by
349 baseline PCR gametocyte densities, can be found in supplementary table 24 (appendix 1 p 38).
350 ACT-PQ was significantly faster than all other regimens at gametocyte clearance ($p < 0.0001$ in
351 all comparisons; supplementary tables 25-26, appendix 1 pp 39-40). Gametocytes detectable
352 by microscopy persisted after day 28 in the DHA-PPQ, SP-AQ, PY-AS, AL and non-ACT-PQ
353 groups, while gametocytes were microscopically undetectable by day 14 in the ACT-PQ group
354 and by day 21 in the ACT-TQ group. Gametocytes measured by RT-qPCR (limit of detection
355 of 0.01 gametocytes/ μ L) persisted in a subset of individuals in all treatment groups until the
356 end of follow-up.

357 **DISCUSSION**

358 This pooled analysis from individual patient data compares the transmission-blocking activity
359 of different regimens of schizonticidal drugs with or without a single low-dose gametocytocide
360 in *P. falciparum* gametocyte carriers in Mali. We found a marked difference between the
361 different ACTs, with AL causing the largest reduction in mosquito infection rate (97.10%)
362 within 48 hours of treatment initiation. The impact of DHA-PPQ, PY-AS and AS-AQ on
363 transmission were significantly less than AL and led to prolonged gametocyte carriage and
364 infectivity post-treatment. Adding a single low-dose of primaquine (0.25 or 0.5 mg/kg) to any
365 ACT accelerated the clearance of gametocytes and led to a significantly greater reduction in
366 mosquito infection rate within 48-hours of treatment.

367 The effectiveness and utility of the treatments in the six studies analysed here have been
368 discussed in depth in the original trial reports (21–26). This combined analysis represents the
369 first synthesis of this data and direct comparison of these treatments. A number of treatments
370 were tested in multiple studies (DHA-PPQ, DHA-PPQ plus 0.25 mg/kg PQ, AL and SP-AQ)
371 and our results were highly concordant across years (supplementary figure 7, appendix 1, p
372 29), evidence of the value of established transmission testing facilities and the appropriateness
373 of a pooled analysis. Prior to these trials, there was sparse evidence of the gametocytocidal and
374 transmission reducing efficacy for many of the included treatments. The available data
375 frequently originated from single studies, used disparate and insensitive methodologies for
376 gametocyte quantification, or did not conduct transmission assays to determine the
377 transmissibility of gametocytes (28–32). This was the rationale for including only studies with
378 highly similar enrolment criteria and assessments, including transmission assays before and
379 after initiation of treatment.

380 This pooled analysis confirms SP-AQ's poor ability to clear gametocytes and reduce
381 transmission, with a significantly lower relative reduction in mosquito infection rate at day 7
382 compared to DHA-PPQ, AS-AQ, and AL. As the only non-artemisinin-based antimalarial
383 recommended for systematic distribution via seasonal malaria chemoprevention (SMC) (33),
384 SP-AQ's poor performance against gametocytes may reduce the overall community impact of
385 SMC; adding a single low-dose of primaquine to SP-AQ for chemoprevention, would likely
386 improve this.

387 This pooled analysis provides the first direct comparison of SLD primaquine and SLD
388 tafenoquine with the same partner drug. Our analysis indicates a delayed but highly effective
389 response of SLD tafenoquine compared to SLD primaquine when combined with ACTs,
390 achieving a 99.37% reduction in mosquito infection rate at day 7 from baseline. Although the
391 transmission-blocking efficacy of tafenoquine is dose-dependent, our pooled analysis
392 combined the two highest dose groups (0.83 mg/kg and 1.66 mg/kg) for simplicity, possibly
393 obscuring the effects of the higher dose. Despite these delayed transmission-blocking
394 properties of TQ compared with SLD primaquine in our findings, its long half-life could be a
395 major advantage and could be of relevance to prevent the transmission of drug resistant
396 parasites, which may have an increased gametocyte conversion rate and transmission potential
397 (34,35).

398 Before ACTs were introduced, several antimalarials including chloroquine and sulfadoxine-
399 pyrimethamine were reported to increase gametocytaemia and/or infectivity after treatment
400 (36,37). Our analysis, almost exclusively examining ACTs, did not find evidence for post-
401 treatment enhancement of infectivity although we did observe that a non-negligible proportion
402 of individuals became infectious after treatment (this proportion being $\geq 10\%$ of participants in
403 the DHA-PPQ, SP-AQ, PY-AS and AS-AQ groups); this percentage was below 2% in the

404 remaining treatment groups, including AL. The fact that very few individuals become
405 gametocyte positive or infectious after AL suggests that, among ACT regimens, AL may be
406 superior at targeting immature or sequestered gametocytes.

407 The presence of gametocytes after treatment at densities that normally permit transmission does
408 not make transmission an inevitability, because gametocytes may be sterilized or become non-
409 infectious for other reasons before being cleared (12). In this pooled analysis, this discordance
410 was most pronounced in the AL group and groups with SLD PQ, where post-treatment effects
411 on infectivity preceded gametocyte clearance. In all other treatment groups, reductions in
412 gametocyte density and mosquito infection rate followed more similar patterns. The
413 combination of an ACT with SLD PQ was significantly faster than all other regimens at
414 gametocyte clearance (100% of microscopical gametocytes by day 14), while ACT-TQ was
415 the second fastest regimen to clear gametocytes (100% of microscopical gametocytes by day
416 21). Infectivity clearance was the fastest in the treatment groups with SLD PQ, followed by
417 AL.

418 A few limitations in our study warrant consideration. Firstly, we established transmission-
419 blocking activity in highly infectious individuals. This population allows a detailed assessment
420 of transmission-blocking properties; however, post-treatment transmission potential is likely
421 to be smaller in the majority of malaria patients who predominantly have submicroscopic
422 gametocyte densities or may even be free of gametocytes at clinical presentation. A different
423 study would be needed to determine the relative importance of sub- vs microscopic gametocyte
424 carriage for malaria transmission in clinical patients though these would likely require larger
425 sample sizes for mosquito infectivity endpoints. Secondly, our study utilized direct membrane
426 feeding assays rather than direct skin feeding, which may have resulted in reduced infectivity,
427 despite no compelling evidence of gametocytes sequestering in the skin (38). In addition, we

428 measured oocyst prevalence instead of sporozoite prevalence and some infected mosquitoes
429 may not have become infectious (39). Nevertheless, comparisons between groups remain valid,
430 and we observed a strong association between oocyst prevalence and oocyst densities,
431 indicating that a higher proportion of infected mosquitoes reflects a greater transmission
432 potential. Lastly, this pooled analysis set out to assess the ability of antimalarial treatment to
433 prevent the transmission of drug-resistant parasites. Considering that gametocytes in
434 *PfKelch13* mutant infections might preferentially survive artemisinin exposure and infect
435 mosquitoes (35), our findings regarding ACTs may not be generalisable to areas where
436 artemisinin partial resistance is present. In addition, increased gametocytaemia was found to
437 be an early indicator of resistance emergence against previous non-ACT first-line treatments
438 (34). Consequently, while our results indicate that AL is nearly as effective as ACT-PQ in
439 reducing mosquito infection rates, it remains unclear whether this would extend to settings with
440 artemisinin-resistant malaria infections. Our data on SLD gametocytocides in combination
441 with ACTs therefore supports the 2023 advice from the WHO malaria policy and advisory
442 group to expand the focus on reducing parasite transmission with SLD PQ in areas where
443 partial artemisinin resistance has been detected (20). Additionally, we observed high
444 transmission-blocking efficacy of AL when administered as a directly observed therapy (DOT);
445 its efficacy may be lower in real-life settings where treatment adherence may be lower.

446 In conclusion, utilizing individual patient-level data from six clinical trials conducted at the
447 same study site with highly consistent transmission experiments across trials, we showed
448 pronounced differences in anti-gametocyte and anti-transmission effects between ACTs, with
449 AL showing the most effectiveness in blocking transmission. Additionally, our findings
450 confirm the rapid effects of SLD PQ in clearing and sterilizing gametocytes when used in
451 combination with an ACT, while the addition of an SLD TQ to ACTs has a delayed
452 transmission-blocking effect compared to SLD PQ. Lastly, our analysis confirms considerably

453 higher post-treatment transmission after SP-AQ compared to most ACTs, and adding an SLD
454 PQ to SP-AQ may be beneficial to block malaria transmission in community treatment
455 campaigns.

456 **Data Availability Statement**

457 All trial data are available through a novel open-access clinical epidemiology database
458 resource, ClinEpiDB; and code for analysis and the selection of data used for this analysis can
459 be found on <https://github.com/leenvh/NECTAR-pooled-analysis>.

460 **Funding**

461 The original studies were supported by the Bill & Melinda Gates Foundation (OPP1013179,
462 OPP1089413, INV-002098, INV-005735); LNV is further supported by a Biotechnology and
463 Biological Sciences Research Council LIDo Ph.D. studentship (BB/T008709/1). WS is
464 supported by a Wellcome Trust fellowship (218676/Z/19/Z/WT) and Jordache Ramjith and
465 Teun Bousema by a VICI fellowship from the Dutch Research Council (NWO; grant number
466 09150182210039).

467 **Competing interests**

468 The authors have declared that no competing interests exist

469 **Acknowledgements**

470 We would like to thank everyone involved in the original studies, including the local safety
471 monitor, members of the data safety and monitoring board, and all MRTC study staff for their

472 assistance and support. Finally, we are thankful to all study participants and the population of
473 Ouélessébougou, Mali, for their cooperation.

474 **Author contributions**

475 LNV, JR, AM, CD, AD, WS and TB conceived the study. AM, MJS, MER, LNV, KS, YS,
476 SMN, MD, SM, SK, SS, AY, HD, SFT, RG, JMB, CD, AD, WS and TB conceived and
477 undertook individual studies. KL performed molecular analyses. JR, LNV, AM, RG, JMB, CD,
478 AD, WS and TB analysed the data and interpreted results. LNV, JR, WS and TB wrote the first
479 draft of the manuscript. All authors reviewed and edited the manuscript and read and approved
480 the final manuscript.

481

482 **TABLES**

483

484 **Table 1. Overview of the included studies.** Rows in grey indicate treatment groups that
485 were not included in the analyses.
486

Study	Year	Treatment group	Number of participants	Treatment category	Study population	Reference
PQ01	2013-2014	DHA-PPQ	16	DHA-PPQ	G6PD+ males, 5-50 years, ≥ 32 gametocytes/ μ L	(24)
		DHA-PPQ + 0.0625 mg/kg PQ	16	/		
		DHA-PPQ + 0.125 mg/kg PQ	17	/		
		DHA-PPQ + 0.25 mg/kg PQ	15	ACT-PQ		
		DHA-PPQ + 0.5 mg/kg PQ	17	ACT-PQ		
PQ03	2016	SP-AQ	20	SP-AQ	G6PD+ males, 5-50 years, asymptomatic, ≥ 16 gametocytes/ μ L	(23)
		SP-AQ + 0.25 mg/kg PQ	20	Non-ACT-PQ		
		DHA-PPQ	20	DHA-PPQ		
		DHA-PPQ + MB	20	/		
NECTAR1	2019	DHA-PPQ	25	DHA-PPQ	Males and non-pregnant females, 5-50 years, asymptomatic, ≥ 16 gametocytes/ μ L	(25)
		DHA-PPQ + 0.25 mg/kg PQ	25	ACT-PQ		
		PY-AS	25	PY-AS		
		PY-AS + 0.25 mg/kg PQ	25	ACT-PQ		
NECTAR2	2020	DHA-PPQ	20	DHA-PPQ	G6PD+ males and non-pregnant females, 12-50 years, asymptomatic, ≥ 16 gametocytes/ μ L	(22)
		DHA-PPQ + 0.42 mg/kg TQ	20	/		
		DHA-PPQ + 0.83 mg/kg TQ	20	ACT-TQ		
		DHA-PPQ + 1.66 mg/kg TQ	20	ACT-TQ		
NECTAR3	2021	AL	20	AL	G6PD+ males and non-pregnant females, 10-50 years, asymptomatic, ≥ 16 gametocytes/ μ L	(21)
		AL + 0.25 mg/kg PQ	20	ACT-PQ		
		SP-AQ	20	SP-AQ		
		SP-AQ + 1.66 mg/kg TQ	20	/		
NECTAR4	2022	AL	20	AL	Males and non-pregnant females, 10-50 years, asymptomatic, ≥ 16 gametocytes/ μ L	(26)
		AL-AQ	20	AL		
		AL-AQ + 0.25 mg/kg PQ	20	ACT-PQ		
		AS-AQ	20	AS-AQ		
		AS-AQ + 0.25 mg/kg PQ	20	ACT-PQ		

487

488

489 FIGURE LEGENDS

490

491 **Figure 1. Study design of included trials.** All studies assessed infectivity to mosquitoes
492 before (d0), during (d2) and one and two weeks after initiation of treatment (d7 and d14) with
493 additional time-points that differed between studies. Tick marks represent days; circles
494 indicate sampling/screening time points. Circles that are encompassed by larger red circles
495 indicate that a standard dose schizonticide was administered at these study visits, while a
496 single low-dose gametocytocide was administered at the time points with a larger blue circle.
497 Grey coloured circles indicate that parasite densities were assessed by both microscopy
498 (asexual parasite and gametocyte densities) and RT-qPCR (gametocyte densities). At other
499 study visits, parasite densities were determined by microscopy only (white circles) or RT-
500 qPCR only (dark grey circles). Mosquito infectivity assays were conducted at the study visits
501 marked with a black mosquito symbol, while a grey mosquito symbol indicates that mosquito
502 infectivity assays were only conducted at that time point if any of the previous two assays
503 resulted in at least one infected mosquito.

504

505 **Figure 2. Baseline study characteristics.** **A.** Violin plot of microscopical asexual parasite
506 density (parasites/ μ L) distribution per study. **B.** Violin plot of microscopical gametocyte
507 density (gametocytes/ μ L) distribution per study. **C.** The mean proportion of mosquitoes that
508 became infected after feeding on venous blood collected at enrolment, prior to treatment, per
509 study. Vertical bars represent 95% CIs estimated from a logistic regression model. **D.** Results
510 from a logistic regression between microscopically determined gametocyte densities
511 (gametocytes / μ L) on a log₁₀ scale and the proportion of infected mosquitoes over the
512 different study years shown by the different colours. Mosquito feeding assays in this analysis
513 were conducted before treatment was initiated. The black line indicates the overall trend
514 averaged across all years with the shaded area showing the 95% confidence interval for this
515 overall fit. Visualisations represent a total of 422 observations, from 42 (2013-2014), 60
516 (2016), 100 (2019), 60 (2020), 60 (2021) and 100 (2022) study participants. The median
517 number of dissected mosquitoes per study participant (panel C) was 71.8 (IQR 65.6-77) for
518 2013-2014, 79 (IQR 72-84) for 2016, 64 (IQR 57-70) for 2019, 60 (IQR 51.8-66.5) for 2020,
519 62 (IQR 53.8-64.2) for 2021 and 61 (IQR 55-66) for 2022.

520

521

522 **Figure 3. Gametocyte prevalence and densities.** **A.** scatter plot of the association between
523 gametocyte density measured by microscopy (x-axis) and RT-qPCR (y-axis) pre-treatment,
524 both on a log₁₀ scale. A linear model with an interaction by year was used to estimate the
525 study specific trend lines (shown in colour with estimated slopes (β) indicated in the legend).
526 A linear mixed effects model was used to estimate the trend line averaged across the study
527 years ($\beta=0.94$) shown by the black line, and the corresponding 95% CI, shown by the grey
528 shaded area. The dashed line represents the line of equality where measurements by
529 microscopy and PCR would be equal. **B-D.** Bar charts illustrating the relative reduction
530 compared to baseline in gametocyte prevalence by microscopy (**B**), and gametocyte densities
531 measured by microscopy (**C**) and molecular methods (**D**), by treatment arm over three time
532 points (Day 2 - indigo, Day 7 - turquoise, and Day 14 - green). Vertical bars depict the 95%
533 confidence intervals for these estimates. Due to inflated standard errors the y-axis was cut off
534 below -50. Visualisations represent data from 422 individuals at baseline (79, 40, 25, 20, 60,
535 20, 138 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, non-ACT-PQ,
536 ACT-PQ and ACT-TQ groups, respectively). At day 2, 369 individuals were included (65,
537 39, 23, 20, 58, 19, 105 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL,
538 Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Data from 357 individuals at

539 day 7 is shown (57, 38, 24, 20, 57, 19, 104 and 38 individuals from the DHA-PPQ, SP-AQ,
540 PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Day 14
541 includes data from 357 individuals (60, 38, 24, 19, 57, 18, 105 and 36 individuals from the
542 DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups,
543 respectively).

544

545 **Figure 4. Infectivity of submicroscopic gametocyte infections and the relative reduction**
546 **in the proportion of infected mosquitoes compared to baseline per treatment category.**

547 **A.** Stacked bar chart representing the number of observations for each proportion of infected
548 mosquitoes (rounded to the nearest integer) at baseline and at days 2, 7 and 14 post-treatment
549 initiation. For each day of follow-up, individual study participants contribute a single
550 observation. Bars are coloured by the presence of gametocytes by microscopy (blue) or by
551 PCR only (orange). Baseline visualisations represent a total of 422 study participants; per
552 study 42 (2013-2014), 60 (2016), 100 (2019), 60 (2020), 60 (2021) and 100 (2022)
553 participants were enrolled and presented here. At day 2, data from 375 individuals are
554 presented (60, 99, 60, 58, 98 participants from the 2016, 2019, 2020, 2021 and 2022 studies,
555 respectively). At day 7 post-treatment initiation, 367 participants are presented (56, 98, 59, 58
556 and 97 participants from the 2016, 2019, 2020, 2021 and 2022 studies, respectively). Finally,
557 at day 14, data from 218 individuals are presented (47, 56, 17 and 96 participants from the
558 2019, 2020, 2021 and 2022 studies, respectively). **B.** Bar chart illustrating the relative
559 reduction compared to baseline in the proportion of infected mosquitoes by treatment arm
560 over three time points (Day 2 - indigo, Day 7 - turquoise, and Day 14 - green). Vertical bars
561 depict the 95% confidence intervals for these estimates. Visualisations represent data from
562 416 individuals at baseline (79, 40, 25, 20, 60, 20, 139 and 40 individuals from the DHA-
563 PPQ, SP-AQ, PY-AS, AS-AQ, AL, non-ACT-PQ, ACT-PQ and ACT-TQ groups,
564 respectively). At day 2, 416 individuals were included (78, 40, 25, 20, 58, 20, 135 and 40
565 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and
566 ACT-TQ groups, respectively). Data from 409 individuals at day 7 is shown (76, 39, 25, 20,
567 57, 19, 134 and 39 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-
568 PQ, ACT-PQ and ACT-TQ groups, respectively). Day 14 includes data from 218 individuals
569 (43, 15, 25, 19, 39, 40 and 37 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL,
570 ACT-PQ and ACT-TQ groups, respectively).

571

572 **Figure 5. Between-group comparison of the reduction in proportion infected mosquitoes**
573 **at days 2 and 7 post-treatment, compared to baseline.** Heatmaps representing the

574 percentage reduction in the proportion infection mosquitoes per treatment category at day 2
575 (A) and day 7 (B) compared to baseline in the top cells, with 95% confidence intervals and p-
576 value comparing to baseline. Other cells in the heatmap represent the p-values comparing
577 treatment groups. Heatmap cells are coloured by the absolute difference between treatment
578 groups in the relative reduction in proportion infected mosquitoes at days 2 and 7 post-
579 treatment, compared to baseline. For example, DHA-PPQ achieves 20.35% reduction in the
580 proportion of infected mosquitoes by day 2 compared to 97.10% for AL; the difference
581 between these arms (76.75% lower reduction for DHA-PPQ) is statistically significant
582 ($p < 0.0001$).

583

584 **Figure 6. Time to clearance of infectivity and gametocytes per treatment category.**

585 Kaplan-Meier survival curves showing the cumulative probability of remaining uncleared of
586 gametocytes detected by microscopy (purple), gametocytes detected by PCR (turquoise) and
587 infectivity to mosquitos (green) over time stratified across different antimalarial treatment

588 categories (DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ, ACT-TQ).
589 Shaded areas indicate 95% confidence intervals for the Kaplan-Meier survival estimates.
590 Survival curves showing infectivity represent data from 417 individuals (79, 40, 25, 20, 58,
591 20, 135 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ,
592 ACT-PQ and ACT-TQ groups, respectively). Survival curves visualising gametocytes by
593 microscopy show data from 375 individuals (65, 40, 25, 20, 58, 20, 107 and 40 individuals
594 from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ
595 groups, respectively) and 417 individuals (79, 40, 25, 20, 58, 20, 135 and 40 individuals from
596 the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups,
597 respectively) for gametocyte assessment by RT-qPCR.
598

599 REFERENCES

- 600 1. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents*
601 *Chemother.* 1997 Jul;41(7):1413–22.
- 602 2. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG, et al. Quantitative assessment of
603 *Plasmodium falciparum* sexual development reveals potent transmission-blocking activity by methylene blue.
604 *Proc Natl Acad Sci U S A.* 2011 Nov 22;108(47):E1214-1223.
- 605 3. Bousema T, Drakeley C. Epidemiology and Infectivity of *Plasmodium falciparum* and *Plasmodium vivax*
606 Gametocytes in Relation to Malaria Control and Elimination. *Clin Microbiol Rev.* 2011 Apr;24(2):377–410.
- 607 4. Stepniewska K, Humphreys GS, Gonçalves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of Single-Dose
608 Primaquine With Artemisinin Combination Therapy on *Plasmodium falciparum* Gametocytes and Transmission:
609 An Individual Patient Meta-Analysis. *The Journal of Infectious Diseases.* 2022 Apr 1;225(7):1215–26.
- 610 5. Bolscher JM, Koolen KMJ, Van Gemert GJ, Van De Vegte-Bolmer MG, Bousema T, Leroy D, et al. A
611 combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct
612 dynamics of marketed and experimental drugs. *Journal of Antimicrobial Chemotherapy.* 2015 May
613 1;70(5):1357–66.
- 614 6. Lelièvre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, et al. Activity of Clinically Relevant
615 Antimalarial Drugs on *Plasmodium falciparum* Mature Gametocytes in an ATP Bioluminescence “Transmission
616 Blocking” Assay. Waller RF, editor. *PLoS ONE.* 2012 Apr 13;7(4):e35019.
- 617 7. van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M, van Gemert GJ, Rottmann M, et al. The
618 Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks *Plasmodium*
619 *falciparum* Transmission to Anopheles Mosquito Vector. *Antimicrob Agents Chemother.* 2012 Jul;56(7):3544–8.
- 620 8. Chavalitshewinkoon-Petmitr P, Pongvilairat G, Auparakkitanon S, Wilairat P. Gametocytocidal activity of
621 pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant *Plasmodium falciparum* in vitro.
622 *Parasitology International.* 2000 Feb;48(4):275–80.
- 623 9. Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, et al. Male and Female
624 *Plasmodium falciparum* Mature Gametocytes Show Different Responses to Antimalarial Drugs. *Antimicrob*
625 *Agents Chemother.* 2013 Jul;57(7):3268–74.
- 626 10. Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, et al. Submicroscopic
627 *Plasmodium falciparum* gametocyte densities frequently result in mosquito infection. *Am J Trop Med Hyg.* 2007
628 Mar;76(3):470–4.
- 629 11. Butcher GA. Development of malaria blood-stage vaccines: learning from mosquitoes. *Transactions of the Royal*
630 *Society of Tropical Medicine and Hygiene.* 2007 Jun;101(6):530–1.
- 631 12. Bradley J, Soumaré HM, Mahamar A, Diawara H, Roh M, Delves M, et al. Transmission-blocking Effects of
632 Primaquine and Methylene Blue Suggest *Plasmodium falciparum* Gametocyte Sterilization Rather Than Effects
633 on Sex Ratio. *Clinical Infectious Diseases.* 2019 Sep 27;69(8):1436–9.
- 634 13. White NJ, Ashley EA, Recht J, Delves MJ, Ruecker A, Smithuis FM, et al. Assessment of therapeutic responses
635 to gametocytocidal drugs in *Plasmodium falciparum* malaria. *Malar J.* 2014 Dec 9;13:483.
- 636 14. Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin
637 partial resistance in Africa: how do we respond? *The Lancet Infectious Diseases.* 2024
638 Mar;S1473309924001415.
- 639 15. Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TNA, White NJ, et al. Preventing antimalarial drug
640 resistance with triple artemisinin-based combination therapies. *Nat Commun.* 2023 Jul 29;14(1):4568.
- 641 16. Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, et al. Optimum population-level use of
642 artemisinin combination therapies: a modelling study. *Lancet Glob Health.* 2015 Dec;3(12):e758-766.

- 643 17. World Health Organization. World malaria report 2023 [Internet]. World Health Organization; 2023 [cited 2023
644 Dec 11]. Available from: [https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022)
645 2022
- 646 18. Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus
647 Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria. *N Engl J Med*. 2019 Jan 17;380(3):229–41.
- 648 19. World Health Organization. Global Malaria Programme: WHO policy brief on single-dose primaquine as
649 gametocytocide in *Plasmodium falciparum* malaria. 2015.
- 650 20. World Health Organization. WHO Malaria Policy Advisory Group (MPAG) meeting report [Internet]. 2023
651 [cited 2023 Nov 15]. Available from: [https://iris.who.int/bitstream/handle/10665/368391/9789240074385-](https://iris.who.int/bitstream/handle/10665/368391/9789240074385-eng.pdf?sequence=1)
652 eng.pdf?sequence=1
- 653 21. Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niamebele SM, Sacko A, et al. Artemether–lumefantrine with or
654 without single-dose primaquine and sulfadoxine–pyrimethamine plus amodiaquine with or without single-dose
655 tafenoquine to reduce *Plasmodium falciparum* transmission: a phase 2, single-blind, randomised clinical trial in
656 Ouelessebougou, Mali. *The Lancet Microbe*. 2024 Jul;5(7):633–44.
- 657 22. Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niamebele SM, et al. Single low-dose tafenoquine
658 combined with dihydroartemisinin–piperaquine to reduce *Plasmodium falciparum* transmission in
659 Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. *The Lancet Microbe*. 2022
660 May;3(5):e336–47.
- 661 23. Dicko A, Roh ME, Diawara H, Mahamar A, Harouna M, Soumare, Lanke K, et al. Efficacy and safety of
662 primaquine and methylene blue for prevention of *Plasmodium falciparum* transmission in Mali: a phase 2, single-
663 blind, randomised controlled trial. *Lancet Infect Dis*. 2018 Jun;18(6):627–39.
- 664 24. Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to reduce transmission of
665 *Plasmodium falciparum* malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. *Lancet*
666 *Infect Dis*. 2016 Jun;16(6):674–84.
- 667 25. Stone W, Mahamar A, Sanogo K, Sinaba Y, Niamebele SM, Sacko A, et al. Pyronaridine–artesunate or
668 dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent *Plasmodium falciparum*
669 malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial. *The Lancet*
670 *Microbe*. 2022 Jan;3(1):e41–51.
- 671 26. Mahamar A, Vanheer LN, Smit MJ, Sanogo K, Sinaba Y, Niamebele SM, et al. Artemether-lumefantrine-
672 amodiaquine or artesunate-amodiaquine combined with single low-dose primaquine to reduce *Plasmodium*
673 *falciparum* malaria transmission in Ouélessébougou, Mali: a five-arm, phase 2, single-blind, randomised clinical
674 trial. *MedRXiv*. 2024;
- 675 27. Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. A protocol for membrane
676 feeding assays to determine the infectiousness of *P. falciparum* naturally infected individuals to *Anopheles*
677 *gambiae*. 2013;4(16):4.
- 678 28. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for
679 clearance of *Plasmodium falciparum* gametocytes in children with uncomplicated malaria in Uganda: a
680 randomised, controlled, double-blind, dose-ranging trial. *Lancet Infect Dis*. 2014 Feb;14(2):130–9.
- 681 29. Okebe J, Bousema T, Affara M, DiTanna G, Eziefula AC, Jawara M, et al. The gametocytocidal efficacy of
682 primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia
683 (PRINOGAM): study protocol for a randomised controlled trial. *Trials*. 2015 Mar 1;16:70.
- 684 30. Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, et al. Single low dose primaquine
685 to reduce gametocyte carriage and *Plasmodium falciparum* transmission after artemether-lumefantrine in children
686 with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. *BMC Med* [Internet]. 2016
687 Mar 8 [cited 2021 Jun 12];14. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782330/>
- 688 31. Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of
689 primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated
690 *Plasmodium falciparum* malaria in Tanzania. *Malar J*. 2016 Jun 10;15:316.

- 691 32. Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gonçalves BP, et al. Safety of single low-dose
692 primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label,
693 randomized, safety trials. *PLoS One*. 2018;13(1):e0190272.
- 694 33. World Health Organization. Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus
695 amodiaquine in children: a field guide, second edition. 2023.
- 696 34. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, et al. Increased Gametocytemia after
697 Treatment: An Early Parasitological Indicator of Emerging Sulfadoxine-Pyrimethamine Resistance in
698 Falciparum Malaria. *J INFECT DIS*. 2008 Jun;197(11):1605–13.
- 699 35. Witmer K, Dahalan FA, Delves MJ, Yahiya S, Watson OJ, Straschil U, et al. Transmission of Artemisinin-
700 Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. *Antimicrobial Agents and
701 Chemotherapy*. 2020 Dec 16;65(1):e00898-20.
- 702 36. Sokhna CS, Trape JF, Robert V. Gametocytaemia in senegalese children with uncomplicated Falciparum malaria
703 treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine. *Parasite*. 2001 Sep 1;8(3):243–50.
- 704 37. Enosse S, Butcher GA, Margos G, Mendoza J, Sinden RE, Høgh B. The mosquito transmission of malaria: the
705 effects of atovaquone-proguanil (Malarone™) and chloroquine. *Transactions of the Royal Society of Tropical
706 Medicine and Hygiene*. 2000 Jan;94(1):77–82.
- 707 38. Meibalan E, Barry A, Gibbins MP, Awandu S, Meerstein-Kessel L, Achcar F, et al. Plasmodium falciparum
708 Gametocyte Density and Infectivity in Peripheral Blood and Skin Tissue of Naturally Infected Parasite Carriers
709 in Burkina Faso. *J Infect Dis*. 2019 Dec 26;223(10):1822–30.
- 710 39. Stone WJR, Eldering M, Van Gemert GJ, Lanke KHW, Grignard L, Van De Vegte-Bolmer MG, et al. The
711 relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. *Sci Rep*. 2013 Dec
712 4;3(1):3418.
- 713




Figure 1




Figure2







Figure3





Figure4



A**B**

Figure 5




Figure6